All In Biotech

NDA 020827 · Medtech Products

Monistat 3

Miconazole Nitrate · Vaginal

Last checked: Nov 20, 2026Latest source record: Sep 15, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Mar 30, 1998

Approved uses

1

Original approval plus efficacy supplements

Registered trials

36

8 Phase 3, 0 recruiting

FAERS reports

1,906

792 serious, 87 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 23, 2025.

Use treats vaginal yeast infections

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • MONISTAT 3 · MICONAZOLE NITRATE 4% · CREAM, VAGINAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Miconazole Nitrate" as an intervention, any sponsor and status, largest first.

All 36 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vulvovaginal burning sensation424
  • drug ineffective193
  • vulvovaginal pain184
  • vulvovaginal pruritus147
  • vaginal haemorrhage113
  • condition aggravated97
  • vulvovaginal discomfort96
  • pain77
  • burning sensation72
  • pruritus71
  • off label use64
  • drug interaction60

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200420
200515
200621
200712
200838
200957
201037
201150
201280
201325
201430
201531
2016105
201782
2018125
201969
2020116
2021149
2022171
2023119
2024160
2025196
2026198

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 71 on PubMed

Sponsor: Medtech Products

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.